Tuberculosis and Respiratory Diseases

  • 제70권5호
  • /
  • Pages.405-415
  • /
  • 2011
  • /
  • 1738-3536(pISSN)
  • /
  • 2005-6184(eISSN)
대한결핵및호흡기학회 (The Korean Academy of Tuberculosis and Respiratory Diseases)
권호 표지
DOI QR코드

DOI QR Code

TGF-${\beta}1$으로 자극한 사람중피세포주에서 조직플라스미노겐 활성제가 미치는 영향

The Effect of Tissue Plasminogen Activator on TGF-${\beta}1$ Pre-Treated Human Mesothelial Cell Line

  • 이정림 (건양대학교 의과대학 미생물학교실) ;
  • 전수진 (건양대학교 의과대학 미생물학교실) ;
  • 유영춘 (건양대학교 의과대학 미생물학교실) ;
  • 김지혜 (건양대학교 의과대학 내과학교실) ;
  • 이유미 (건양대학교 의과대학 내과학교실) ;
  • 권선중 (건양대학교 의과대학 내과학교실) ;
  • 손지웅 (건양대학교 의과대학 내과학교실) ;
  • 최유진 (건양대학교 의과대학 내과학교실) ;
  • 나문준 (건양대학교 의과대학 내과학교실)
  • Lee, Jung-Lim (Department of Microbiology, Konyang University College of Medicine) ;
  • Jeon, Soo-Jin (Department of Microbiology, Konyang University College of Medicine) ;
  • Yoo, Young-Choon (Department of Microbiology, Konyang University College of Medicine) ;
  • Kim, Ji-Hye (Department of Internal Medicine, Konyang University College of Medicine) ;
  • Lee, Yu-Mi (Department of Internal Medicine, Konyang University College of Medicine) ;
  • Kwon, Sun-Jung (Department of Internal Medicine, Konyang University College of Medicine) ;
  • Son, Ji-Woong (Department of Internal Medicine, Konyang University College of Medicine) ;
  • Choi, Eu-Gene (Department of Internal Medicine, Konyang University College of Medicine) ;
  • Na, Moon-Jun (Department of Internal Medicine, Konyang University College of Medicine)
  • 투고 : 2011.01.07
  • 심사 : 2011.04.04
  • 발행 : 2011.05.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: In an effort to find alternative therapeutic agents to prevent excessive fibrosis as a sequela to complicated parapneumonic effusion or empyema, we examined the effect of tissue plasminogen activator (tPA) as a fibrinolytic agent combined with talc or transforming growth factor (TGF)-${\beta}1$ in a human pleural mesothelial cell line, MeT-5A. Methods: MeT-5A cells were stimulated with various doses of talc, doxycycline or TGF-${\beta}1$ for 24 h and then were treated with tPA for an additional 24 h. Cell viability was measured by MTT assay. The production of interleukin (IL)-8 and vascular endothelial growth factor (VEGF) in the culture supernatants was measured by ELISA. Real-time PCR was carried out for measurement of type I collagen mRNA. Results: MeT-5A cells treated with talc showed a dose-dependent increase in production of IL-8. Talc also increased production of type I collagen mRNA at low doses, but talc did not influence the induction of VEGF. Addition of tPA to talc-stimulated cells showed further increases in the production of IL-8, but tPA did not influence the production of VEGF or type I collagen mRNA. TGF-${\beta}1$ increased the production of both VEGF and collagen type I mRNA, both of which were effectively inhibited by additional tPA treatment in MeT-5A cells. Conclusion: TGF-${\beta}1$ is a potent inducer of collagen synthesis without induction of IL-8 in MeT-5A cells. Addition of tPA after TGF-${\beta}1$ stimulation inhibited further fibrosis by direct inhibition of collagen mRNA synthesis as well as by inhibition of VEGF production.

키워드

참고문헌

  1. Leard LE, Broaddus VC. Mesothelial cell proliferation and apoptosis. Respirology 2004;9:292-9. https://doi.org/10.1111/j.1440-1843.2004.00602.x
  2. Iakhiaev AV, Nalian A, Koenig K, Idell S. Thrombin- thrombomodulin inhibits prourokinase-mediated pleural mesothelial cell-dependent fibrinolysis. Thromb Res 2007;120:715-25. https://doi.org/10.1016/j.thromres.2006.12.001
  3. Lee YC, Knight DA, Lane KB, Cheng DS, Koay MA, Teixeira LR, et al. Activation of proteinase-activated receptor- 2 in mesothelial cells induces pleural inflammation. Am J Physiol Lung Cell Mol Physiol 2005;288:L734-40. https://doi.org/10.1152/ajplung.00173.2004
  4. Diacon AH, Theron J, Schuurmans MM, Van de Wal BW, Bolliger CT. Intrapleural streptokinase for empyema and complicated parapneumonic effusions. Am J Respir Crit Care Med 2004;170:49-53. https://doi.org/10.1164/rccm.200312-1740OC
  5. Misthos P, Sepsas E, Konstantinou M, Athanassiadi K, Skottis I, Lioulias A. Early use of intrapleural fibrinolytics in the management of postpneumonic empyema. A prospective study. Eur J Cardiothorac Surg 2005;28:599-603. https://doi.org/10.1016/j.ejcts.2005.07.005
  6. Maskell NA, Davies CW, Nunn AJ, Hedley EL, Gleeson FV, Miller R, et al. U.K. Controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med 2005;352:865-74. https://doi.org/10.1056/NEJMoa042473
  7. Niedbala MJ, Picarella MS. Tumor necrosis factor induction of endothelial cell urokinase-type plasminogen activator mediated proteolysis of extracellular matrix and its antagonism by gamma-interferon. Blood 1992;79:678-87.
  8. Lee SR, Guo SZ, Scannevin RH, Magliaro BC, Rhodes KJ, Wang X, et al. Induction of matrix metalloproteinase, cytokines and chemokines in rat cortical astrocytes exposed to plasminogen activators. Neurosci Lett 2007;417:1-5. https://doi.org/10.1016/j.neulet.2007.01.017
  9. Ray TL, Berkenbosch JW, Russo P, Tobias JD. Tissue plasminogen activator as an adjuvant therapy for pleural empyema in pediatric patients. J Intensive Care Med 2004;19:44-50. https://doi.org/10.1177/0885066603259942
  10. Bishop NB, Pon S, Ushay HM, Greenwald BM. Alteplase in the treatment of complicated parapneumonic effusion: a case report. Pediatrics 2003;111:E188-90. https://doi.org/10.1542/peds.111.2.e188
  11. Walker CA, Shirk MB, Tschampel MM, Visconti JA. Intrapleural alteplase in a patient with complicated pleural effusion. Ann Pharmacother 2003;37:376-9. https://doi.org/10.1345/aph.1C248
  12. Weinstein M, Restrepo R, Chait PG, Connolly B, Temple M, Macarthur C. Effectiveness and safety of tissue plasminogen activator in the management of complicated parapneumonic effusions. Pediatrics 2004;113:e182-5. https://doi.org/10.1542/peds.113.3.e182
  13. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63. https://doi.org/10.1016/0022-1759(83)90303-4
  14. Mutsaers SE, Prele CM, Brody AR, Idell S. Pathogenesis of pleural fibrosis. Respirology 2004;9:428-40. https://doi.org/10.1111/j.1440-1843.2004.00633.x
  15. Kennedy L, Harley RA, Sahn SA, Strange C. Talc slurry pleurodesis. Pleural fluid and histologic analysis. Chest 1995;107:1707-12. https://doi.org/10.1378/chest.107.6.1707
  16. Light RW. Talc for pleurodesis? Chest 2002;122:1506-8. https://doi.org/10.1378/chest.122.5.1506
  17. Light RW, Cheng DS, Lee YC, Rogers J, Davidson J, Lane KB. A single intrapleural injection of transforming growth factor-beta(2) produces an excellent pleurodesis in rabbits. Am J Respir Crit Care Med 2000;162:98-104. https://doi.org/10.1164/ajrccm.162.1.9909106
  18. Lee YC, Lane KB, Zoia O, Thompson PJ, Light RW, Blackwell TS. Transforming growth factor-beta induces collagen synthesis without inducing IL-8 production in mesothelial cells. Eur Respir J 2003;22:197-202. https://doi.org/10.1183/09031936.03.00086202
  19. Kalomenidis I, Guo Y, Lane KB, Hawthorne M, Light RW. Transforming growth factor-beta3 induces pleurodesis in rabbits and collagen production of human mesothelial cells. Chest 2005;127:1335-40. https://doi.org/10.1378/chest.127.4.1335
  20. Gary Lee YC, Melkerneker D, Thompson PJ, Light RW, Lane KB. Transforming growth factor beta induces vascular endothelial growth factor elaboration from pleural mesothelial cells in vivo and in vitro. Am J Respir Crit Care Med 2002;165:88-94. https://doi.org/10.1164/ajrccm.165.1.2104006
  21. Sasse SA, Jadus MR, Kukes GD. Pleural fluid transforming growth factor-beta1 correlates with pleural fibrosis in experimental empyema. Am J Respir Crit Care Med 2003;168:700-5. https://doi.org/10.1164/rccm.2202043
  22. Samarakoon R, Higgins SP, Higgins CE, Higgins PJ. TGF-beta1-induced plasminogen activator inhibitor-1 expression in vascular smooth muscle cells requires pp60(c-src)/EGFR(Y845) and Rho/ROCK signaling. J Mol Cell Cardiol 2008;44:527-38. https://doi.org/10.1016/j.yjmcc.2007.12.006
  23. Grove CS, Lee YC. Vascular endothelial growth factor: the key mediator in pleural effusion formation. Curr Opin Pulm Med 2002;8:294-301. https://doi.org/10.1097/00063198-200207000-00009
  24. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999;77:527-43. https://doi.org/10.1007/s001099900019
  25. Boussat S, Eddahibi S, Coste A, Fataccioli V, Gouge M, Housset B, et al. Expression and regulation of vascular endothelial growth factor in human pulmonary epithelial cells. Am J Physiol Lung Cell Mol Physiol 2000;279:L371-8. https://doi.org/10.1152/ajplung.2000.279.2.L371
  26. Koochekpour S, Merzak A, Pilkington GJ. Vascular endothelial growth factor production is stimulated by gangliosides and TGF-beta isoforms in human glioma cells in vitro. Cancer Lett 1996;102:209-15. https://doi.org/10.1016/0304-3835(96)04161-4
  27. Donovan D, Harmey JH, Toomey D, Osborne DH, Redmond HP, Bouchier-Hayes DJ. TGF beta-1 regulation of VEGF production by breast cancer cells. Ann Surg Oncol 1997;4:621-7. https://doi.org/10.1007/BF02303745
  28. Thickett DR, Armstrong L, Millar AB. Vascular endothelial growth factor (VEGF) in inflammatory and malignant pleural effusions. Thorax 1999;54:707-10. https://doi.org/10.1136/thx.54.8.707
  29. Cheng D, Rodriguez RM, Perkett EA, Rogers J, Bienvenu G, Lappalainen U, et al. Vascular endothelial growth factor in pleural fluid. Chest 1999;116:760-5. https://doi.org/10.1378/chest.116.3.760
  30. Gervais DA, Levis DA, Hahn PF, Uppot RN, Arellano RS, Mueller PR. Adjunctive intrapleural tissue plasminogen activator administered via chest tubes placed with imaging guidance: effectiveness and risk for hemorrhage. Radiology 2008;246:956-63. https://doi.org/10.1148/radiol.2463070235
  31. Levinson GM, Pennington DW. Intrapleural fibrinolytics combined with image-guided chest tube drainage for pleural infection. Mayo Clin Proc 2007;82:407-13. https://doi.org/10.4065/82.4.407
  32. Skeete DA, Rutherford EJ, Schlidt SA, Abrams JE, Parker LA, Rich PB. Intrapleural tissue plasminogen activator for complicated pleural effusions. J Trauma 2004;57:1178-83. https://doi.org/10.1097/01.TA.0000141879.67441.52
  33. Thommi G, Nair CK, Aronow WS, Shehan C, Meyers P, McLeay M. Efficacy and safety of intrapleural instillation of alteplase in the management of complicated pleural effusion or empyema. Am J Ther 2007;14:341-5. https://doi.org/10.1097/01.mjt.0000208275.88120.d1
  34. Zuckerman DA, Reed MF, Howington JA, Moulton JS. Efficacy of intrapleural tissue-type plasminogen activator in the treatment of loculated parapneumonic effusions. J Vasc Interv Radiol 2009;20:1066-9. https://doi.org/10.1016/j.jvir.2009.04.067